Chiome Bioscience (TSE:4583) Total Stockholders Equity: 円1,565.9 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4583 Chiome Bioscience Inc TSE:4583
51 GF Score
Price 円88.00
GF Value 円87.50
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Chiome Bioscience Total Stockholders Equity?

Chiome Bioscience TSE:4583 51 Total Stockholders Equity is 円1,565.9 Mil as of Jun. 2026. GuruFocus rates TSE:4583 with a GF Score™ of 51/100 and a GF Value™ of 円87.50 (Fairly Valued). The stock has 2 warning signs investors should review.

Chiome Bioscience's Total Stockholders Equity for the quarter that ended in Jun. 2026 was 円1,565.9 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Chiome Bioscience's Book Value per Share for the quarter that ended in Jun. 2026 was 円19.84. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Chiome Bioscience's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.04.

Chiome Bioscience  (TSE:4583) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Chiome Bioscience's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(1565.861-0)/78.917381
=19.84

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Chiome Bioscience's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(67.5 + 0) / 1565.861
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chiome Bioscience Total Stockholders Equity Related Terms

Chiome Bioscience Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Chiome Bioscience's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chiome Bioscience Total Stockholders Equity Chart

Chiome Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,893.05 1,790.75 1,157.72 1,920.30 1,122.06

Chiome Bioscience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,519.33 1,250.13 1,122.06 1,311.99 1,565.86
TSE:4583
51GF Score
Chiome Bioscience Inc TSE:4583
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of 円1,565.9 Mil mean?
Chiome Bioscience (TSE:4583) has a Total Stockholders Equity of 円1,565.9 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Chiome Bioscience and its competitors.
Is Chiome Bioscience's Total Stockholders Equity too high?
Chiome Bioscience's current Total Stockholders Equity is 円1,565.9 Mil. Overall, Chiome Bioscience has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chiome Bioscience's Total Stockholders Equity compare to VRTX and REGN?
Chiome Bioscience's Total Stockholders Equity of 円1,565.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Chiome Bioscience and its competitors. Chiome Bioscience's current Total Stockholders Equity is 円1,565.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chiome Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Chiome Bioscience (TSE:4583) is currently considered Fairly Valued. The stock's GF Value™ is 円87.50, compared to a current price of 円88.00 — trading 0.6% above its estimated fair value. The current Total Stockholders Equity is 円1,565.9 Mil. Chiome Bioscience's overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Chiome Bioscience (TSE:4583), the current Total Stockholders Equity is 円1,565.9 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chiome Bioscience (TSE:4583) Overvalued in 2026?

Based on GuruFocus' analysis, Chiome Bioscience stock appears to be overvalued. The current stock price of 円88.00 is trading 0.6% above its estimated GF Value™ of 円87.50. GuruFocus considers Chiome Bioscience to be Fairly Valued.

Key valuation signals for TSE:4583:

  • Total Stockholders Equity: 円1,565.9 Mil
  • GF Value™: 円87.50 vs. price of 円88.00 (0.6% above fair value)
  • GF Score™: 51/100 with 2 warning signs

No single metric tells the full story. See the TSE:4583 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chiome Bioscience Business Description

Address 3-12-1 Honmachi, No. 6, Sumitomo Fudosan Nishi Shinjuku Building, Shibuya-ku, Tokyo, JPN, 151-0071
Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.
51GF Score

Get the complete analysis for TSE:4583

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円88.00
Price
円87.50
GF Value